Lv21
110 积分 2021-11-19 加入
10.1038/d41573-024-00133-0
4小时前
求助中
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
12天前
已完结
Ocular Pharmacokinetics of Faricimab Following Intravitreal Administration in Patients With Retinal Disease
2个月前
已关闭
HER2-Positive Urothelial Carcinoma: Current Evidence on Targeted Agents and Immunotherapy-Based Combinations
2个月前
已完结
Visual Acuity Gain With Ranibizumab Therapy: Two-Year Data From the Marina, Anchor, and Pier Trials in Patients With Neovascular Amd
3个月前
已关闭
Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration
3个月前
已完结
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study
3个月前
已完结
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
3个月前
已完结
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
3个月前
已完结
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
3个月前
已完结
皖公网安备34019202002308
